RecruitingPhase 4NCT05285839
Dupixent and Narrowband UVB for Atopic Dermatitis
Single Center, Pilot Study to Evaluate the Effectiveness and Safety of Dupilumab in Combination With Narrowband UVB (nUVB) Phototherapy in the Treatment of Moderate-to-Severe Atopic Dermatitis
Sponsor
Psoriasis Treatment Center of Central New Jersey
Enrollment
40 participants
Start Date
Apr 19, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Male or female adult ≥ 18 years of age;
- Diagnosis of moderate to severe atopic dermatitis as defined at baseline by:
- EASI score of 16 or greater,
- IGA score of 3 or greater
- BSA of 10% or greater,
Exclusion Criteria3
- Subjects with previous exposure to dupilumab.
- Known or suspected hypersensitivity to dupilumab or any of its excipients.
- History of photosensitivity.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGDupixent
dupilumab 300mg
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05285839
Related Trials
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
NCT072629831 location
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
NCT0700342545 locations
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
NCT0729080343 locations
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
NCT0727766050 locations
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
NCT050422581 location